COVID Vaccine Update: AstraZeneca Used Old Data, J&J Facing Supply Issues, Florida Vindicated

AstraZeneca is facing scrutiny after problematic data in their submission to federal regulators and Johnson & Johnson’s vaccine production hit a snag with supply chain problems. There still may be enough to vaccinate all Americans.


In preparing for a request for emergency use authorization in the United States, pharmaceutical company AstraZeneca released data showing its coronavirus vaccine had a 79% effectiveness.

  • Less than a day later, the National Institutes of Health released a statement saying AstraZeneca “may have included outdated information” in its application, potentially providing “an incomplete view of the efficacy data.”
  • Even before the NIH’s concerns, AstraZeneca was struggling to regain its footing after a similar data blunder in the United Kingdom and recent unfounded fears over the vaccine causing blood clots.
  • Meanwhile, Johnson & Johnson, which has created the only approved single-dose vaccine, is facing “logistical constraints”, leading the Biden administration to questions whether J&J will be able to meet its commitments.


reporting from the left side of the aisle




  • Fox News’ coverage of the NIH’s questioning AstraZeneca’s data included recent remarks from the company’s president defending the vaccine.
  • OANN’s coverage relied heavily on wire reports, pitting the countries of the EU and the United Kingdom against AstraZeneca, which the EU characterizes as having oversold its production capacity, leaving the continent woefully short on vaccines.
  • The Federalist highlighted the vaccination successes of Florida, saying the ability to vaccinate 70% of seniors has vindicated Gov. Ron DeSantis after the flak he received in the media for months.


Return to Freespoke

© Dallas Gerber, 2021